Breast Cancer

Temporary ovarian suppression using triptorelin may decrease the rate of early menopause in premenopausal women with early-stage breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine

Dr. Michael Dixon from University of Edinburgh on Systems Biology Determining Therapy Combinations

Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment

Radiotherapy can be given between or during chemotherapy cycles, rather than sequentially, for women with early breast cancer.

Weekly high-dose vitamin D supplementation improves joint and muscle pain related to anastrozole therapy in breast cancer patients with low vitamin D levels.

T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.

Dr. Donald McDonald from UCSF Comprehensive Cancer Center Explains Approved Angiogenesis Inhibitors

Now more than ever, oncology nurses need to be able to fill the knowledge gap and accurately educate their patients and the public about cancer screening tests and their frequency.

Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity

Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor

Dr. J. Michael Dixon from University of Edinburgh on Letrozole Used in Combination With Pathway Inhibitors

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Triple Negative Breast Cancer Treatment

Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms

Dr. J. Michael Dixon from University of Edinburgh on Advances in Breast Cancer Systemic Therapy

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Next Step for Angiogenesis Inhibitors

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

Dr. Hope S. Rugo from UCSF Cancer Center on the Future of Angiogenesis in Breast Cancer

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Treatment

Dr. Donald M. McDonald from the UCSF Cancer Center Discusses Resistance to Angiogenesis Inhibitors

Dr. J. Michael Dixon from the University of Edinburgh on Advances in Breast Cancer Axillary Node Procedures

Detecting breast cancer using mammography and self-examination was affirmed in a study that sharply contrasts the controversial 2009 USPSTF recommendations.

Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors

A new set of statistical models will soon be available to help predict the risk of lymphedema for patients with breast cancer who have undergone ALND.

Women age 40 and younger with breast cancer experience similar outcomes in local recurrence and survival rates whether they undergo BCT or a mastectomy.